Nuvalent NUVL
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Nuvalent (NUVL) Business Model and Operations Summary
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Key Insights
Nuvalent (NUVL) Core Market Data and Business Metrics
Latest Closing Price
$68Market Cap
$4.90 BillionPrice-Earnings Ratio
-17.30Total Outstanding Shares
66.16 Million SharesTotal Employees
142Dividend
No dividendIPO Date
July 29, 2021SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
One Broadway, 14th Floor, Cambridge, MA, 02142
Historical Stock Splits
If you bought 1,200,000 shares of NUVL before March 10, 2017, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| March 10, 2017 | 1-for-1200000 (Reverse Split) |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $-185.06 Million |
| Net Cash Flow From Financing Activities, Continuing | $568.88 Million |
| Net Cash Flow | $-189.70 Million |
| Net Cash Flow From Investing Activities | $-573.51 Million |
| Net Cash Flow From Operating Activities, Continuing | $-185.06 Million |
| Net Cash Flow, Continuing | $-189.70 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Parent | $-260.76 Million |
| Net Income/Loss | $-260.76 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Diluted Earnings Per Share | $-3.93 |
| Research and Development | $217.77 Million |
| Other Operating Expenses | $62.59 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-260.85 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $-90,000 |
| Comprehensive Income/Loss Attributable To Parent | $-260.85 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Parent | $1.07 Billion |
| Current Liabilities | $54.02 Million |
| Liabilities | $71.96 Million |
| Equity | $1.07 Billion |
| Equity Attributable To Noncontrolling Interest | $0 |
| Noncurrent Assets | $9.30 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||